Business Standard

Orchid Pharma antibiotic product for treating UTI coming to India: MD

Company says it's returning to profit after takeover by Dhanuka Laboratories under insolvency resolution

pharma
Premium

Enmetazobactam, in combination with cefepime, addresses the need to tackle bacteria developing resistance against antibiotics

Sohini Das Mumbai
Orchid Pharma, which was taken over by Dhanuka Laboratories under insolvency resolution in March 2020, is making a turn-around in revenue and profit as it commercialises a molecule developed in-house, said its senior executive.

Manish Dhanuka, managing director of Chennai-based Orchid Pharma, told Business Standard the new chemical entity (NCE) is known as Enmetazobactam. The molecule is a BLI (Beta-lactamase Inhibitor) used in combination with beta-lactam antibiotic cefepime.

“The drug product which has completed global clinical trials is a combination of Enmetazobactam with Cefepime. This is an injectable product, which is highly effective in treating complicated Urinary Tract Infections (cUTI),” Dhanuka

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 24 2022 | 2:04 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com